Vera Therapeutics (VERA) Assets Average (2021 - 2026)

Vera Therapeutics (VERA) has 6 years of Assets Average data on file, last reported at $678.2 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 7.16% year-over-year to $678.2 million; the trailing twelve-month figure through Mar 2026 stood at $678.2 million (up 7.16% YoY), and the FY2025 full-year result was $695.2 million, up 67.27% from the prior year.
• Assets Average for Q1 2026 stood at $678.2 million, up from $626.1 million in the prior quarter.
• Across five years, Assets Average topped out at $678.2 million in Q1 2026 and bottomed at $124.4 million in Q1 2022.
• The 5-year median for Assets Average is $297.5 million (2024), against an average of $351.0 million.
• The widest annual swing landed in 2024, when Assets Average surged 191.67%; it then advanced 7.16% in 2026.
• A 5-year view of Assets Average shows it stood at $131.4 million in 2022, then soared by 33.62% to $175.6 million in 2023, then soared by 191.67% to $512.1 million in 2024, then gained by 22.26% to $626.1 million in 2025, then climbed by 8.32% to $678.2 million in 2026.
• The last three Assets Average figures came in at $678.2 million (Q1 2026), $626.1 million (Q4 2025), and $548.0 million (Q3 2025), per Business Quant data.

Peer Comparison